GCGuo Chen

Guo Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Guo Chen has a total of 56 co-authors. Here are the top co-authors by number of shared publications:

  • Yushan Zhu

    State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Responses, Center for Aging and Regeneration, Tianjin Key Laboratory of Protein Science, College of Life Sciences, Nankai University, Tianjin, China

    3 shared publications
  • Baofa Sun

    State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Responses, College of Life Sciences, Nankai University, Tianjin, China

    2 shared publications
  • Fengcongzhe Gong

    State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Responses, College of Life Sciences, Nankai University, Tianjin, China

    2 shared publications
  • Hong Lei

    State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Responses, Center for Aging and Regeneration, Tianjin Key Laboratory of Protein Science, College of Life Sciences, Nankai University, Tianjin, China

    2 shared publications
  • Jiaojiao Zhang

    State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Responses, Center for Aging and Regeneration, Tianjin Key Laboratory of Protein Science, College of Life Sciences, Nankai University, Tianjin, China

    2 shared publications
  • Jiaxing Sun

    State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Responses, Center for Aging and Regeneration, Tianjin Key Laboratory of Protein Science, College of Life Sciences, Nankai University, Tianjin, China

    2 shared publications

Latest Publications

  • The IKKε-GABPA axis regulates STING transcription to orchestrate antiviral immunity and inflammation

    by Jiaojiao Zhang, Tian Zhao, Hong Lei, Rui Gan, Xin Liu, Yuanyuan Meng, Dongfeng Ren, Jingyi Su, Yinmei Tang, Jiaxing Sun, et al.

    The cGAS–STING pathway plays a critical role in antiviral defense and inflammatory homeostasis. While posttranslational regulation of STING is well characterized, the transcriptional networks directly governing Sting1 expression remain unclear. Here, we identify the transcription factor GA-binding protein alpha (GABPA) as a critical regulator of STING-dependent type I IFN (IFN-I) responses in macrophages. Mechanistically, GABPA directly binds to the Sting1 promoter, thereby transcriptionally sustaining basal STING expression. Upon viral infection, activated IκB kinase epsilon (IKKε) phosphorylates GABPA at S447, which further enhances its transcriptional activity and amplifies the STING–IFN-I signaling cascade. Notably, Gabpa deficiency protects mice from DSS-induced colitis, and this protective effect is abolished upon Sting1 deletion. Strikingly, patients with inflammatory bowel disease (IBD) or systemic lupus erythematosus (SLE) exhibit elevated GABPA expression that positively correlates with STING hyperactivation and enhanced inflammatory signatures. Moreover, a GABPA-blocking peptide effectively suppresses aberrant IFN-β production in peripheral blood mononuclear cells (PBMCs) from SLE patients, highlighting its therapeutic potential for interferonopathies.

  • Open Access

    Author Correction: NRF1-mediated innate immune response drives inflammaging

    by Hong Lei, Tian Zhao, Jiaojiao Zhang, Yijia Long, Yongze Chen, Yixuan Zhu, Yuanyuan Meng, Yinmei Tang, Xin Liu, Jiaxing Sun, et al.

  • Open Access

    NRF1-mediated innate immune response drives inflammaging

    by Hong Lei, Tian Zhao, Jiaojiao Zhang, Yijia Long, Yongze Chen, Yixuan Zhu, Yuanyuan Meng, Yinmei Tang, Xin Liu, Jiaxing Sun, et al.

    Aberrant innate immune responses contribute significantly to cellular senescence, yet the precise interplay between innate immunity and senescence remains poorly characterized. Here, we elucidate the pivotal role of nuclear respiratory factor 1 (NRF1) in orchestrating innate immune responses that drive senescence and the senescence-associated secretory phenotype (SASP). NRF1 deficiency delayed cellular senescence and ameliorated age-related deterioration in multiple organs. Mechanistically, NRF1 enhanced SASP by transcriptionally regulating TBK1 and IRF3, critical nodes in innate immunity essential for senescence induction. Conversely, NRF1 deficiency suppressed innate immune activation, thereby attenuating inflammation associated with senescence and aging. Additionally, DNA damage activated ATM kinase, which phosphorylated NRF1 at Ser393, augmenting the NRF1-TBK1/IRF3-type I interferon axis and exacerbating cellular senescence. Furthermore, NRF1 knockdown treatment effectively mitigated aging phenotypes and extended lifespan in aged mice. Collectively, our findings underscore the essential role of the ATM-NRF1-TBK1/IRF3-type I interferon axis in DNA damage-induced senescence, suggesting that targeted NRF1 modulation holds therapeutic promise for improving inflammaging.


  • Open Access

    3,4-dimethoxychalcone induces autophagy and reduces neointimal hyperplasia and aortic lesions in mouse models of atherosclerosis

    by Giulia Cerrato, Carlota Alvarez-Lucena, Allan Sauvat, Yanhua Hu, Sabrina Forveille, Guo Chen, Sylvère Durand, Fanny Aprahamian, Marion Leduc, Omar Motiño, et al.

    Autophagy inducers can prevent cardiovascular aging and age-associated diseases including atherosclerosis. Therefore, we hypothesized that autophagy-inducing compounds that act on atherosclerosis-relevant cells might have a protective role in the development of atherosclerosis. Here we identified 3,4-dimethoxychalcone (3,4-DC) as an inducer of autophagy in several cell lines from endothelial, myocardial and myeloid/macrophagic origin, as demonstrated by the aggregation of the autophagosome marker GFP-LC3 in the cytoplasm of cells, as well as the downregulation of its nuclear pool indicative of autophagic flux. In this respect, 3,4-DC showed a broader autophagy-inducing activity than another chalcone (4,4- dimethoxychalcone), spermidine and triethylene tetramine. Thus, we characterized the potential antiatherogenic activity of 3,4-DC in two different mouse models, namely, (i) neointima formation with smooth muscle expansion of vein segments grafted to the carotid artery and (ii) genetically predisposedApoE−/−mice fed an atherogenic diet. In the vein graft model, local application of 3,4-DC was able to maintain the lumen of vessels and to reduce neointima lesions. In the diet-induced model, intraperitoneal injections of 3,4-DC significantly reduced the number of atherosclerotic lesions in the aorta. In conclusion, 3,4-DC stands out as an autophagy inducer with potent antiatherogenic activity.


  • Open Access

    Innate immunity and immunotherapy for hemorrhagic shock

    by Qingxia Huang, Song Gao, Yao Yao, Yisa Wang, Jing Li, Jinjin Chen, Chen Guo, Daqing Zhao, Xiangyan Li

    Hemorrhagic shock (HS) is a shock result of hypovolemic injury, in which the innate immune response plays a central role in the pathophysiology ofthe severe complications and organ injury in surviving patients. During the development of HS, innate immunity acts as the first line of defense, mediating a rapid response to pathogens or danger signals through pattern recognition receptors. The early and exaggerated activation of innate immunity, which is widespread in patients with HS, results in systemic inflammation, cytokine storm, and excessive activation of complement factors and innate immune cells, comprised of type II innate lymphoid cells, CD4+ T cells, natural killer cells, eosinophils, basophils, macrophages, neutrophils, and dendritic cells. Recently, compelling evidence focusing on the innate immune regulation in preclinical and clinical studies promises new treatment avenues to reverse or minimize HS-induced tissue injury, organ dysfunction, and ultimately mortality. In this review, we first discuss the innate immune response involved in HS injury, and then systematically detail the cutting-edge therapeutic strategies in the past decade regarding the innate immune regulation in this field; these strategies include the use of mesenchymal stem cells, exosomes, genetic approaches, antibody therapy, small molecule inhibitors, natural medicine, mesenteric lymph drainage, vagus nerve stimulation, hormones, glycoproteins, and others. We also reviewed the available clinical studies on immune regulation for treating HS and assessed the potential of immune regulation concerning a translation from basic research to clinical practice. Combining therapeutic strategies with an improved understanding of how the innate immune system responds to HS could help to identify and develop targeted therapeutic modalities that mitigate severe organ dysfunction, improve patient outcomes, and reduce mortality due to HS injury.